These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 26411545)

  • 1. The HIV glycan shield as a target for broadly neutralizing antibodies.
    Doores KJ
    FEBS J; 2015 Dec; 282(24):4679-91. PubMed ID: 26411545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
    Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
    J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages.
    Behrens AJ; Kumar A; Medina-Ramirez M; Cupo A; Marshall K; Cruz Portillo VM; Harvey DJ; Ozorowski G; Zitzmann N; Wilson IA; Ward AB; Struwe WB; Moore JP; Sanders RW; Crispin M
    J Proteome Res; 2018 Mar; 17(3):987-999. PubMed ID: 29420040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.
    Schorcht A; Cottrell CA; Pugach P; Ringe RP; Han AX; Allen JD; van den Kerkhof TLGM; Seabright GE; Schermer EE; Ketas TJ; Burger JA; van Schooten J; LaBranche CC; Ozorowski G; de Val N; Bader DLV; Schuitemaker H; Russell CA; Montefiori DC; van Gils MJ; Crispin M; Klasse PJ; Ward AB; Moore JP; Sanders RW
    J Virol; 2022 Jan; 96(1):e0155221. PubMed ID: 34669426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
    Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
    PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies.
    Boutin M; Vézina D; Ding S; Prévost J; Laumaea A; Marchitto L; Anand SP; Medjahed H; Gendron-Lepage G; Bourassa C; Goyette G; Clark A; Richard J; Finzi A
    mBio; 2022 Jun; 13(3):e0057722. PubMed ID: 35475646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140.
    Go EP; Herschhorn A; Gu C; Castillo-Menendez L; Zhang S; Mao Y; Chen H; Ding H; Wakefield JK; Hua D; Liao HX; Kappes JC; Sodroski J; Desaire H
    J Virol; 2015 Aug; 89(16):8245-57. PubMed ID: 26018173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.
    Coss KP; Vasiljevic S; Pritchard LK; Krumm SA; Glaze M; Madzorera S; Moore PL; Crispin M; Doores KJ
    J Virol; 2016 Dec; 90(24):11132-11144. PubMed ID: 27707925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural principles controlling HIV envelope glycosylation.
    Behrens AJ; Crispin M
    Curr Opin Struct Biol; 2017 Jun; 44():125-133. PubMed ID: 28363124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.
    Behrens AJ; Harvey DJ; Milne E; Cupo A; Kumar A; Zitzmann N; Struwe WB; Moore JP; Crispin M
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27807235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.
    Rathore U; Saha P; Kesavardhana S; Kumar AA; Datta R; Devanarayanan S; Das R; Mascola JR; Varadarajan R
    J Biol Chem; 2017 Jun; 292(24):10197-10219. PubMed ID: 28446609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope.
    Barnes CO; Gristick HB; Freund NT; Escolano A; Lyubimov AY; Hartweger H; West AP; Cohen AE; Nussenzweig MC; Bjorkman PJ
    Nat Commun; 2018 Mar; 9(1):1251. PubMed ID: 29593217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.
    Lee JH; Andrabi R; Su CY; Yasmeen A; Julien JP; Kong L; Wu NC; McBride R; Sok D; Pauthner M; Cottrell CA; Nieusma T; Blattner C; Paulson JC; Klasse PJ; Wilson IA; Burton DR; Ward AB
    Immunity; 2017 Apr; 46(4):690-702. PubMed ID: 28423342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses to the HIV-1 envelope high mannose patch.
    Daniels CN; Saunders KO
    Adv Immunol; 2019; 143():11-73. PubMed ID: 31607367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers.
    Pritchard LK; Vasiljevic S; Ozorowski G; Seabright GE; Cupo A; Ringe R; Kim HJ; Sanders RW; Doores KJ; Burton DR; Wilson IA; Ward AB; Moore JP; Crispin M
    Cell Rep; 2015 Jun; 11(10):1604-13. PubMed ID: 26051934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsecond Dynamics and Network Analysis of the HIV-1 SOSIP Env Trimer Reveal Collective Behavior and Conserved Microdomains of the Glycan Shield.
    Lemmin T; Soto C; Stuckey J; Kwong PD
    Structure; 2017 Oct; 25(10):1631-1639.e2. PubMed ID: 28890362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
    Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
    J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational Heterogeneity of the HIV Envelope Glycan Shield.
    Yang M; Huang J; Simon R; Wang LX; MacKerell AD
    Sci Rep; 2017 Jun; 7(1):4435. PubMed ID: 28667249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions.
    Wang S; Voronin Y; Zhao P; Ishihara M; Mehta N; Porterfield M; Chen Y; Bartley C; Hu G; Han D; Wells L; Tiemeyer M; Lu S
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycans in HIV-1 vaccine design - engaging the shield.
    Deimel LP; Xue X; Sattentau QJ
    Trends Microbiol; 2022 Sep; 30(9):866-881. PubMed ID: 35279348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.